Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Integrated histopathological and urinary metabonomic investigation of the pathogenesis of microcystin-LR toxicosis.

Cantor GH, Beckonert O, Bollard ME, Keun HC, Ebbels TM, Antti H, Wijsman JA, Bible RH, Breau AP, Cockerell GL, Holmes E, Lindon JC, Nicholson JK.

Vet Pathol. 2013 Jan;50(1):159-71. doi: 10.1177/0300985812443839. Epub 2012 May 2.

PMID:
22552484
2.

Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide.

Maddox JF, Luyendyk JP, Cosma GN, Breau AP, Bible RH Jr, Harrigan GG, Goodacre R, Ganey PE, Cantor GH, Cockerell GL, Roth RA.

Toxicol Appl Pharmacol. 2006 Apr 1;212(1):35-44. Epub 2005 Jul 27.

PMID:
16051291
3.

Disposition and pharmacokinetics of L-N6-(1-iminoethyl)lysine-5-tetrazole-amide, a selective iNOS inhibitor, in rats.

Zhang JY, Wang Y, Milton MN, Kraus L, Breau AP, Paulson SK.

J Pharm Sci. 2004 May;93(5):1229-40.

PMID:
15067699
4.
5.

Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog.

Zhang JY, Wang YF, Milton MN, Beconi M, Chang M, Yin D, Breau AP, Paulson SK.

Xenobiotica. 2003 Nov;33(11):1159-71.

PMID:
14660179
6.
7.

Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism.

Zhang JY, Zhan J, Cook CS, Ings RM, Breau AP.

Drug Metab Dispos. 2003 May;31(5):652-8.

PMID:
12695355
8.

Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project.

Lindon JC, Nicholson JK, Holmes E, Antti H, Bollard ME, Keun H, Beckonert O, Ebbels TM, Reily MD, Robertson D, Stevens GJ, Luke P, Breau AP, Cantor GH, Bible RH, Niederhauser U, Senn H, Schlotterbeck G, Sidelmann UG, Laursen SM, Tymiak A, Car BD, Lehman-McKeeman L, Colet JM, Loukaci A, Thomas C.

Toxicol Appl Pharmacol. 2003 Mar 15;187(3):137-46.

PMID:
12662897
9.

Development and validation of a liquid chromatography-tandem mass spectrometric assay for Eplerenone and its hydrolyzed metabolite in human plasma.

Zhang JY, Fast DM, Breau AP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Apr 25;787(2):333-44.

PMID:
12650756
10.

Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice.

Zhang JY, Yuan JJ, Wang YF, Bible RH Jr, Breau AP.

Drug Metab Dispos. 2003 Apr;31(4):491-501.

PMID:
12642477
11.
12.

A validated SPE-LC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine.

Zhang JY, Fast DM, Breau AP.

J Pharm Biomed Anal. 2003 Feb 5;31(1):103-15.

PMID:
12560054
13.

Determination of valdecoxib and its metabolites in human urine by automated solid-phase extraction-liquid chromatography-tandem mass spectrometry.

Zhang JY, Fast DM, Breau AP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Feb 25;785(1):123-34.

PMID:
12535845
14.

Use of optical biosensor technology to study immunological cross-reactivity between different sulfonamide drugs.

Ahmad A, Ramakrishnan A, McLean MA, Li D, Rock MT, Karim A, Breau AP.

Anal Biochem. 2002 Jan 15;300(2):177-84.

PMID:
11779109
15.

Characterization of metabolites of Celecoxib in rabbits by liquid chromatography/tandem mass spectrometry.

Zhang JY, Wang Y, Dudkowski C, Yang Dc, Chang M, Yuan J, Paulson SK, Breau AP.

J Mass Spectrom. 2000 Nov;35(11):1259-70.

PMID:
11114083
16.

Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey.

Paulson SK, Zhang JY, Jessen SM, Lawal Y, Liu NW, Dudkowski CM, Wang YF, Chang M, Yang D, Findlay JW, Berge MA, Markos CS, Breau AP, Hribar JD, Yuan J.

Xenobiotica. 2000 Jul;30(7):731-44.

PMID:
10963063
17.

Determination of free levels of phenytoin in human plasma by liquid chromatography/tandem mass spectrometry.

Bardin S, Ottinger JC, Breau AP, O'Shea TJ.

J Pharm Biomed Anal. 2000 Aug 15;23(2-3):573-9.

PMID:
10933551
18.

Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.

Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG.

Drug Metab Dispos. 2000 May;28(5):514-21.

PMID:
10772629
19.

Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human.

Paulson SK, Kaprak TA, Gresk CJ, Fast DM, Baratta MT, Burton EG, Breau AP, Karim A.

Biopharm Drug Dispos. 1999 Sep;20(6):293-9.

PMID:
10701700
20.

Effects of LY295427, a low-density lipoprotein (LDL) receptor up-regulator, on LDL receptor gene transcription and cholesterol metabolism in normal and hypercholesterolemic hamsters.

Bensch WR, Gadski RA, Bean JS, Beavers LS, Schmidt RJ, Perry DN, Murphy AT, McClure DB, Eacho PI, Breau AP, Archer RA, Kauffman RF.

J Pharmacol Exp Ther. 1999 Apr;289(1):85-92.

PMID:
10086991
21.

Oxidative and reductive metabolism of 9-cis-retinoic acid in the rat. Identification of 13,14-dihydro-9-cis-retinoic acid and its taurine conjugate.

Shirley MA, Bennani YL, Boehm MF, Breau AP, Pathirana C, Ulm EH.

Drug Metab Dispos. 1996 Mar;24(3):293-302.

PMID:
8820419
22.

Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans.

Franz PM, Mattiuz EL, Hatcher BL, DeSante KA, Breau AP, Occolowitz JL, Dorman DE, Schmid CR, Goldberg MJ, Rubin A.

Drug Metab Dispos. 1993 Mar-Apr;21(2):249-54.

PMID:
8097693
23.

Biotransformation of the antiviral agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and characteristics of a mesoionic ribose metabolite.

Ehlhardt WJ, Wheeler WJ, Breau AP, Chay SH, Birch GM.

Drug Metab Dispos. 1993 Jan-Feb;21(1):162-70.

PMID:
8095212
24.

Characterization of LY233569 on 5-lipoxygenase and reperfusion injury of ischemic myocardium.

Hahn RA, MacDonald BR, Simpson PJ, Wang L, Towner RD, Ho PP, Goodwin M, Breau AP, Suarez T, Mihelich ED.

J Pharmacol Exp Ther. 1991 Jan;256(1):94-102.

PMID:
1988671
25.

Mutagenic and cell transformation activities of representative phosphorothioate esters in vitro.

Breau AP, Mitchell WM, Swinson J, Field L.

J Toxicol Environ Health. 1985;16(3-4):403-13.

PMID:
4087308
26.

Thiono compounds. 4. In vitro mutagenic and antineoplastic activity of TEPA and thio-TEPA.

Breau AP, Field L, Mitchell WM.

Cell Biol Toxicol. 1984 Oct;1(1):21-30.

PMID:
6086064
27.

Thiono compounds. 3. Chemical oxidation of thioacetamide to a mutagenic S-oxide.

Breau AP, Mitchell WM, Karkhanis DW, Field L.

Mutat Res. 1984 Jan;139(1):1-4. No abstract available.

PMID:
6361546
28.

Mechanism of action of methyldopa in the rat. Role of 3-O-methylated metabolites.

Zavisca FG, Breau AP, Wurtman RJ.

Circ Res. 1979 Nov;45(5):684-90.

PMID:
487531

Supplemental Content

Loading ...
Support Center